ClinicalTrials.gg
TerminatedNCT01075815Updated Feb 13, 2014Results posted

A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age

A Phase 2 interventional study of Recombinant human luteinizing hormone (rhLH) and Recombinant follicle-stimulating hormone (rFSH) in Infertility and Ovulation Induction, sponsored by Merck KGaA, Darmstadt, Germany. Terminated at 1 site in Spain. Open to female participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2014-02-13.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
35 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing lutropin alfa in Infertility — 1 open to participants now, 1 under way, 1 of them phase 3. lutropin alfa · Infertility.

Enrollment
8th of 11
76 · median 90
Started
2008
the only one that year
Phase 2
3 of 11
none open now
Registered
3rd of 11
by date
Lead sponsor
3 of 11
Merck KGaA, Darmstadt, Germany

Among the 11 studies testing lutropin alfa in Infertility, this one is the 8th largest by enrollment, is the only one that started in 2008, is one of 3 in phase 2, and was the 3rd registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

1 of the 11 studies testing lutropin alfa in Infertility is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lutropin alfa

lutropin alfa: first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 35 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing lutropin alfa in Infertility, or all of them as a file.
02

Study summary

This is a multicentric, open, randomized, comparative trial aimed to assess the influence of recombinant luteinizing hormone (r-LH) supplementation during controlled ovarian stimulation (COS) in advanced reproductive age in terms of improved embryo competence which allows to transfer less embryos to avoid high grade multiple pregnancy without reducing the pregnancy rate.

Read the detailed description

This study will be carried out by the Grupo de Interés de Salud Embrionaria (GISE) group (part of the Spanish Fertility Society) who uses strict criteria to select the embryos most suitable for successful transference.

OBJECTIVES

Primary objective:

  • To determine the benefit of r-LH supplementation in COS prior to in-vitro fertilization (IVF)/intracytosolic sperm injection (ICSI) in advanced reproductive age, in terms of embryo competence to implant, as compared against no r-LH supplementation

Secondary objectives:

To evaluate the benefit of r-LH supplementation in COS, in terms of:

  • follicular development
  • length of the stimulation
  • oocyte number and their maturity
  • fertilization rate
  • embryo number and quality
  • gestational sacs
  • abortion
  • ongoing pregnancies
  • local and systemic safety of r-LH administration

The study will consist of 2 groups randomized in 1:1 ratio and each subject would be followed up until the confirmation of her pregnancy status. Each subject will be administered gonadotropin releasing hormone (GnRH) agonist subcutaneously daily from previous mid luteal phase to r-hCG administration as a standard practice to achieve down regulation. Each subject will also be administered recombinant follicle stimulating hormone (r-FSH) at a starting dose of 300 IU from S1 up to ovarian stimulation completion (r-hCG day) as a part of standard practice. In addition to the above concurrent therapies, one group will be administered experimental treatment (Luveris®) and the other group (control group) will not be administered any other drug (control treatment) during the stimulation period from stimulation start (S1) up to ovarian stimulation completion or stimulation cancellation respectively. Ovarian stimulation on an average takes 11 days and it is expected that stimulation period will not be extended beyond 15 days. A single injection of r-hCG will be administered intramuscularly or subcutaneously after the last injection of Luveris or r-FSH to achieve final follicular maturation. After, 34-36 hours of administration of r-hCG OPU will be done for oocyte retrieval and embryo transfer (ET) will be conducted within 5 days from OPU. Subjects will also be provided luteal support with natural progesterone and will be followed until delivery or miscarriage. Ultrasound and estradiol (E2) assessment of follicular growth will be conducted at various time points during the stimulation period with or without treatment adjustment.

03

Conditions studied

  • Infertility
  • Ovulation Induction

Browse trials for

Keywords

  • Infertility
  • Ovulation induction
  • Luveris
  • Controlled ovarian stimulation
  • Reproductive technologies, assisted
04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pre-menopausal female subject aged greater than (>) 35 years
  • Subjects with baseline FSH serum level less than or equal to (\<=) 10 IU/liter (l), LH and E2 levels within local normal range and plasma prolactin levels \< 30 nanogram/milliliter (ng/ml)
  • Subjects with regular spontaneous menstrual cycles of 25-35 days
  • Subjects with infertility justifying IVF/ICSI-ET treatment
  • Subjects programmed for COS with r-FSH under GnRH agonist protocol
  • Sperm from current male partner suitable for IVF/ICSI according to local lab, unless sperm donor is foreseen
  • Subjects with presence of both ovaries
  • Subjects whose uterine cavity is able to sustain embryo implantation or pregnancy
  • Subjects with normal papanicolaou test (PAP) smear within previous 3 years
  • Subjects with (BMI) \< 30 at stimulation start
  • Subjects who receive confirmation of not being pregnant by a negative beta-hCG test (urine or blood) prior to starting r-FSH administration
  • Subjects willing and able to comply with the protocol for the duration of the study
  • Subjects who have given prior to any study-related procedure not part of normal medical care

Exclusion criteria

Exclusion Criteria:

  • Subjects or her male partners who are known to be , virus or virus positive
  • Subjects with any systemic disease; tumors of the hypothalamus and pituitary gland; ovarian, uterine or mammary cancer; hormonal abnormality and/or medical, biochemical, hematological condition which in the judgment of the investigator may interfere with gonadotropin treatment
  • Subjects with more than 2 previous assisted reproductive technologies (ART) cycles
  • Subjects in which previous cycles were cancelled due to poor response (\< 3 antral follicles after 15 day of stimulation)
  • Subjects with cryopreserved embryos from previous ART cycles
  • Subjects with unexplained gynecological bleeding
  • Subjects with polycystic ovaries, ovarian enlargement or cyst of unknown etiology
  • Subjects known to have any to being pregnant and/or carrying pregnancy to term
  • Subjects with known allergy to gonadotrophin preparations or any of the
  • Subjects known to have any active substance abuse or history of drug, medication or alcohol abuse in the past 5 years
  • Subjects with previous entry into this study or simultaneous participation in another clinical drug trial
  • Subjects who have refused to or inability to comply with the protocol
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    rFSH + rhLH

    Recombinant human luteinizing hormone (rhLH,Luveris®) injection 150 IU subcutaneously daily along with rFSH 300 IU subcutaneously daily from S1 to S4 and then rFSH dose can be adjusted depending on the ovarian response till r-hCG administration day.

    Drug: Recombinant human luteinizing hormone (rhLH) · Drug: Recombinant follicle-stimulating hormone (rFSH)

  • Active comparator
    rFSH

    rFSH injection 300 IU subcutaneously daily from S1 to S4 and then dose can be adjusted depending on the ovarian response till r-hCG administration day.

    Drug: Recombinant follicle-stimulating hormone (rFSH)

Interventions

06

What researchers measure

Primary outcomes

  1. Implantation Rate

    Implantation rate was measured as the number of gestational sacs observed, divided by the number of embryos transferred.

    Time frame: Day 35-42 post ovum pick-up (OPU) (34-38 hours post recombinant human choriogonadotropin day {end of stimulation cycle}[approximately 28 days])

Secondary outcomes

  1. Mean Number of Follicles Greater Than or Equal to 14 Millimeter (mm) on Recombinant Human Choriogonadotropin (r-hCG) Day

    Time frame: r-hCG day (end of stimulation cycle [approximately 28 days])

  2. Mean Number of Oocytes Retrieved

    Mean number of oocytes retrieved per reporting group on the day of OPU (34-38 hours post r-hCG day (end of stimulation cycle \[approximately 28 days\]) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.

    Time frame: 34-38 hours post r-hCG day (end of stimulation cycle [approximately 28 days])

  3. Number of Mature Oocytes Retrieved

    Number of mature oocytes retrieved per reporting group on the day of OPU (34-38 hours post r-hCG day (end of stimulation cycle \[approximately 28 days\]) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body. The nuclear maturity was evaluated based on the presence of a germinal vesicle (GV) or whether oocytes were in metaphase I (Meta-I) or II (Meta-II) stage.

    Time frame: 34-38 hours post r-hCG day (end of stimulation cycle [approximately 28 days])

  4. Number of Fertilized Oocytes (2 Pronuclei [PN])

    Oocytes were fertilized using Intra-cytoplasmic Sperm Injection (ICSI) technique which is an in-vitro fertilization procedure in which a single sperm is injected directly into an egg under a microscope. The appearance of two 2PN is the first sign of successful fertilization as observed during in vitro fertilization, and is usually observed after ICSI. The zygote is then termed 2PN.

    Time frame: 34-38 hours post r-hCG day (end of stimulation cycle [approximately 28 days])

  5. Number and Quality of Embryos

    Embryos were graded according to Spanish Association for the Study of Reproductive Biology (ASEBIR) criteria into different categories: (A) optimal quality with maximum capacity for implantation, (B) good quality with a high capacity for implantation, (C) regular with low possibility of implantation and (D) poor quality with very little possibility of implantation.

    Time frame: Day 2-3 post OPU (34-38 hours post r-hCG day {end of stimulation cycle}[approximately 28 days])

  6. Number of Participants With Biochemical Pregnancies

    Biochemical pregnancy was defined as a pregnancy diagnosed only by the detection of hCG in serum or urine and that does not develop into a clinical pregnancy.

    Time frame: 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])

  7. Number of Participants With Clinical Pregnancies

    Clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.

    Time frame: 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])

  8. Total Dose of Recombinant Follicle Stimulating Hormone (r-FSH)

    Time frame: 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])

  9. Estradiol (E2) Levels on r-hCG Day

    Time frame: r-hCG day (end of stimulation cycle [approximately 28 days])

  10. Number of Ovarian Stimulation Days

    Ovarian stimulation included from first rFSH injection (S1) until day on which r-hCG was administered (r-hCG day). This period was divided into 2 parts: the first period in which 300 International Unit (IU) rFSH dose was constant and which covered from S1 to Day 4 of stimulation period (S4); the second period in which the rFSH dose could be adjusted depending on the ovarian response and which began on S4 and finished on the day on which the criteria for administration of r-hCG to induce the final follicular maturation were met.

    Time frame: S1 up to r-hCG day (end of stimulation cycle [approximately 28 days])

  11. Number of Recombinant Human Choriogonadotropin (r-hCG) Cycles Cancelled Due to Poor Response

    Poor response was defined as 3 or less follicles of greater than or equal to 12 mm developing following at least 7 days of study treatment.

    Time frame: Up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])

  12. Total Number of Births

    Total number of births per reporting group was calculated.

    Time frame: Up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])

  13. Number of Participants With Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

    Time frame: Baseline up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])

  14. Number of Participants With Ovarian Hyper Stimulation Syndrome (OHSS)

    OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.

    Time frame: Baseline up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])

  15. Number of Cycles Cancelled Due to Risk of Ovarian Hyper Stimulation Syndrome (OHSS)

    OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.

    Time frame: Baseline up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])

07

Results

Posted Nov 20, 2012

Participant flow

Participant flow — Overall Study
MilestonerFSH + rhLHrFSH
Started4035
Completed3031
Not completed104
Withdrew: Withdrawal before r-hcg administration61
Withdrew: Withdrawal between rhcg-ovum pickup(opu)11
Withdrew: Withdrawal between opu - embryo transfer32

Outcome measures

PrimaryImplantation Rate

Implantation rate was measured as the number of gestational sacs observed, divided by the number of embryos transferred.

Time frame:
Day 35-42 post ovum pick-up (OPU) (34-38 hours post recombinant human choriogonadotropin day {end of stimulation cycle}[approximately 28 days])
Reported as:
Mean · sacs per embryo
Implantation Rate
sacs per embryorFSH + rhLHrFSH
Implantation Rate0.2 ± 0.40.2 ± 0.3
Statistical analysis
  • rFSH + rhLH vs rFSH · Wilcoxon two sample test · p = 0.8762 · Mean difference (final values): 0.0235 · 95% CI -0.1546 to 0.1568
SecondaryMean Number of Follicles Greater Than or Equal to 14 Millimeter (mm) on Recombinant Human Choriogonadotropin (r-hCG) Day
Time frame:
r-hCG day (end of stimulation cycle [approximately 28 days])
Reported as:
Mean · follicles
Mean Number of Follicles Greater Than or Equal to 14 Millimeter (mm) on Recombinant Human Choriogonadotropin (r-hCG) Day
folliclesrFSH + rhLHrFSH
Mean Number of Follicles Greater Than or Equal to 14 Millimeter (mm) on Recombinant Human Choriogonadotropin (r-hCG) Day7.7 ± 4.98.7 ± 4.0
Statistical analysis
  • rFSH + rhLH vs rFSH · ANOVA · p = 0.3589
SecondaryMean Number of Oocytes Retrieved

Mean number of oocytes retrieved per reporting group on the day of OPU (34-38 hours post r-hCG day (end of stimulation cycle \[approximately 28 days\]) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.

Time frame:
34-38 hours post r-hCG day (end of stimulation cycle [approximately 28 days])
Reported as:
Mean · oocytes
Mean Number of Oocytes Retrieved
oocytesrFSH + rhLHrFSH
Mean Number of Oocytes Retrieved5.9 ± 3.97.7 ± 4.0
Statistical analysis
  • rFSH + rhLH vs rFSH · Wilcoxon two sample test · p = 0.0629
SecondaryNumber of Mature Oocytes Retrieved

Number of mature oocytes retrieved per reporting group on the day of OPU (34-38 hours post r-hCG day (end of stimulation cycle \[approximately 28 days\]) was calculated. Oocyte retrieval is a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body. The nuclear maturity was evaluated based on the presence of a germinal vesicle (GV) or whether oocytes were in metaphase I (Meta-I) or II (Meta-II) stage.

Time frame:
34-38 hours post r-hCG day (end of stimulation cycle [approximately 28 days])
Reported as:
Number · mature oocytes
Number of Mature Oocytes Retrieved
mature oocytesrFSH + rhLHrFSH
Number of Mature Oocytes Retrieved234271
Statistical analysis
  • rFSH + rhLH vs rFSH · ANOVA · p = 0.4728
SecondaryNumber of Fertilized Oocytes (2 Pronuclei [PN])

Oocytes were fertilized using Intra-cytoplasmic Sperm Injection (ICSI) technique which is an in-vitro fertilization procedure in which a single sperm is injected directly into an egg under a microscope. The appearance of two 2PN is the first sign of successful fertilization as observed during in vitro fertilization, and is usually observed after ICSI. The zygote is then termed 2PN.

Time frame:
34-38 hours post r-hCG day (end of stimulation cycle [approximately 28 days])
Reported as:
Number · 2PN oocytes
Number of Fertilized Oocytes (2 Pronuclei [PN])
2PN oocytesrFSH + rhLHrFSH
Number of Fertilized Oocytes (2 Pronuclei [PN])128136
Statistical analysis
  • rFSH + rhLH vs rFSH · Fisher Exact · p = 0.0950
SecondaryNumber and Quality of Embryos

Embryos were graded according to Spanish Association for the Study of Reproductive Biology (ASEBIR) criteria into different categories: (A) optimal quality with maximum capacity for implantation, (B) good quality with a high capacity for implantation, (C) regular with low possibility of implantation and (D) poor quality with very little possibility of implantation.

Time frame:
Day 2-3 post OPU (34-38 hours post r-hCG day {end of stimulation cycle}[approximately 28 days])
Reported as:
Number · embyros
Number and Quality of Embryos
embyrosrFSH + rhLHrFSH
A + B (good quality)6965
C + D (poor quality)5673
Total embryos125138
SecondaryNumber of Participants With Biochemical Pregnancies

Biochemical pregnancy was defined as a pregnancy diagnosed only by the detection of hCG in serum or urine and that does not develop into a clinical pregnancy.

Time frame:
2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])
Reported as:
Number · participants
Number of Participants With Biochemical Pregnancies
participantsrFSH + rhLHrFSH
Number of Participants With Biochemical Pregnancies1110
Statistical analysis
  • rFSH + rhLH vs rFSH · Chi-squared · p = 0.9179 · Risk ratio (rr): 0.9625 · 95% CI 0.4655 to 1.9900
SecondaryNumber of Participants With Clinical Pregnancies

Clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.

Time frame:
2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])
Reported as:
Number · participants
Number of Participants With Clinical Pregnancies
participantsrFSH + rhLHrFSH
Number of Participants With Clinical Pregnancies1010
Statistical analysis
  • rFSH + rhLH vs rFSH · Chi-squared · p = 0.7271 · Risk ratio (rr): 0.8750 · 95% CI 0.4133 to 1.8524
SecondaryTotal Dose of Recombinant Follicle Stimulating Hormone (r-FSH)
Time frame:
2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])
Reported as:
Mean · IU
Total Dose of Recombinant Follicle Stimulating Hormone (r-FSH)
IUrFSH + rhLHrFSH
Total Dose of Recombinant Follicle Stimulating Hormone (r-FSH)2812.2 ± 719.42970.3 ± 748.2
Statistical analysis
  • rFSH + rhLH vs rFSH · Wilcoxon two sample test · p = 0.3267
SecondaryEstradiol (E2) Levels on r-hCG Day
Time frame:
r-hCG day (end of stimulation cycle [approximately 28 days])
Reported as:
Mean · picogram/milliter (pg/mL)
Estradiol (E2) Levels on r-hCG Day
picogram/milliter (pg/mL)rFSH + rhLHrFSH
Estradiol (E2) Levels on r-hCG Day1890.2 ± 1084.41621 ± 827.8
Statistical analysis
  • rFSH + rhLH vs rFSH · Wilcoxon two sample test · p = 0.4164
SecondaryNumber of Ovarian Stimulation Days

Ovarian stimulation included from first rFSH injection (S1) until day on which r-hCG was administered (r-hCG day). This period was divided into 2 parts: the first period in which 300 International Unit (IU) rFSH dose was constant and which covered from S1 to Day 4 of stimulation period (S4); the second period in which the rFSH dose could be adjusted depending on the ovarian response and which began on S4 and finished on the day on which the criteria for administration of r-hCG to induce the final follicular maturation were met.

Time frame:
S1 up to r-hCG day (end of stimulation cycle [approximately 28 days])
Reported as:
Mean · Days
Number of Ovarian Stimulation Days
DaysrFSH + rhLHrFSH
Number of Ovarian Stimulation Days9.7 ± 2.19.8 ± 1.9
Statistical analysis
  • rFSH + rhLH vs rFSH · Wilcoxon two sample test · p = 0.5952
SecondaryNumber of Recombinant Human Choriogonadotropin (r-hCG) Cycles Cancelled Due to Poor Response

Poor response was defined as 3 or less follicles of greater than or equal to 12 mm developing following at least 7 days of study treatment.

Time frame:
Up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])
Reported as:
Number · cycles
Number of Recombinant Human Choriogonadotropin (r-hCG) Cycles Cancelled Due to Poor Response
cyclesrFSH + rhLHrFSH
Number of Recombinant Human Choriogonadotropin (r-hCG) Cycles Cancelled Due to Poor Response41
SecondaryTotal Number of Births

Total number of births per reporting group was calculated.

Time frame:
Up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])
Reported as:
Number · births
Total Number of Births
birthsrFSH + rhLHrFSH
Total Number of Births109
Statistical analysis
  • rFSH + rhLH vs rFSH · Chi-squared · p = 0.8852 · Risk ratio (rr): 0.9444 · 95% CI 0.4347 to 2.0518
SecondaryNumber of Participants With Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

Time frame:
Baseline up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsrFSH + rhLHrFSH
Number of Participants With Adverse Events (AEs)199
SecondaryNumber of Participants With Ovarian Hyper Stimulation Syndrome (OHSS)

OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.

Time frame:
Baseline up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])
Reported as:
Number · participants
Number of Participants With Ovarian Hyper Stimulation Syndrome (OHSS)
participantsrFSH + rhLHrFSH
Number of Participants With Ovarian Hyper Stimulation Syndrome (OHSS)10
SecondaryNumber of Cycles Cancelled Due to Risk of Ovarian Hyper Stimulation Syndrome (OHSS)

OHSS is a syndrome which can manifest with enlarged ovaries, advanced ascites with increased vascular permeability, pleural fluid accumulation, hemoconcentration, and increased blood clotting.

Time frame:
Baseline up to 2 months after OPU (34-38 hours post r-hCG day {end of stimulation cycle} [approximately 28 days])
Reported as:
Number · cycles
Number of Cycles Cancelled Due to Risk of Ovarian Hyper Stimulation Syndrome (OHSS)
cyclesrFSH + rhLHrFSH
Number of Cycles Cancelled Due to Risk of Ovarian Hyper Stimulation Syndrome (OHSS)10

Adverse events

Collected over AEs are collected on an ongoing basis from day of written informed consent. All new AEs must be recorded until the post-treatment safety, on day 35-42 post-hCG administration. AEs are classified as pre-treatment, treatment-emergent and post-treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rFSH + rhLH—2/40 (5%)17/40 (42.5%)
rFSH—1/35 (2.9%)8/35 (22.9%)
Most frequent serious events
Most frequent serious events
EventrFSH + rhLHrFSH
Trisomy 13Congenital, familial and genetic disorders0/401/35
New born hip dysplasiaMusculoskeletal and connective tissue disorders1/400/35
Cutaneous anginomaSkin and subcutaneous tissue disorders1/400/35
Most frequent other events
Showing 10 of 30
Most frequent other events
EventrFSH + rhLHrFSH
ErythemaSkin and subcutaneous tissue disorders5/400/35
Pain at the injection siteGeneral disorders5/400/35
PruritusSkin and subcutaneous tissue disorders4/401/35
HeadacheNervous system disorders4/403/35
HaematomaVascular disorders4/401/35
EcchymosisSkin and subcutaneous tissue disorders3/400/35
Subcutaneous haematomaInjury, poisoning and procedural complications2/402/35
DizzinessNervous system disorders1/402/35
PainGeneral disorders1/402/35
Premature birthPregnancy, puerperium and perinatal conditions2/401/35

Baseline characteristics

Age, Continuous
Age, Continuous(years)rFSH + rhLHrFSHTotal
Mean37.2 ± 2.237.3 ± 1.537.2 ± 1.9
Sex: Female, Male
Sex: Female, Male(Participants)rFSH + rhLHrFSHTotal
Female403575
Male000
08

Study locations

1 site
  • FivMadrid, C/ Marqués de Urquijo, 26,
    Madrid, 28008, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2008, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2012, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2010
First posted
Feb 25, 2010
Start
Nov 2008
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Results first posted
Nov 20, 2012
Last update
Feb 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01075815
Collaborators
Merck, S.L., Spain
Responsible party
Sponsor
First posted
Feb 25, 2010
Start date
Nov 2008
Primary completion
Oct 2010
Completion
Oct 2010
Results posted
Nov 20, 2012
Last update
Feb 13, 2014

Study contacts

Medical Responsible
study director · Merck, S.L., Spain

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutropin alfa

Start the discussion